AXL and hepatocellular carcinoma: Notably, inhibition of the CAV1 pathway using CAV1 targeting siCAV1/miR-7 or selective AXL/FGFR4 inhibitor, alone or in combination with sorafenib/lenvatinib, significantly reduced the viability, growth, and invasiveness of TKI-resistant HCC cells.